Clinical trial
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease…
NCT04437511 · Eli Lilly and Company, Industry · Active, not recruiting
Key facts
| NCT number | NCT04437511 |
|---|---|
| Title | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) |
| Official title | Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Donanemab, Placebo |
| Enrollment | 1,736 |
| Start date | Jun 19, 2020 |
| Primary completion | Apr 14, 2023 |
| Completion | Nov 1, 2028 |
| First posted | Jun 18, 2020 |
| Last update posted | Aug 29, 2025 |
| Countries | Australia, Canada, Czechia, Japan, Netherlands, Poland, Puerto Rico, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: